1 Accurately Measuring (And Reporting) Cardiotoxicity: Pitfalls & Proposed Solutions Ronald Witteles, MD October 6, 2011 Stanford University School of Medicine
2 Four Hypotheses Hypothesis 1: Product labeling is often a mess Hypothesis 2: Cardiotoxicity definitions in CTCAE 4.0 are in desperate need of reform Hypothesis 3: Those who don t learn from history are doomed to repeat it. Hypothesis 4: This matters
3 Hypothesis 1: Product Labeling is Often a Mess
4 Doxorubicin Label (2011) Treatment of doxorubicin-induced congestive heart failure includes the use of digitalis, diuretics, afterload reducers such as ACE-inhibitors, low salt diet, and bed rest. Such intervention may relieve symptoms and improve the functional status of the patient. The probability of developing impaired myocardial function is estimated to be: 300 mg/m 2 : 1-2% 400 mg/m 2 : 3-5% 450 mg/m 2 : 5-8% 500 mg/m 2 : 6-20% Adapted from Doxorubicin Prescribing Information
5 Doxorubicin: Dose-Relationships 1979: Report by Von Hoff et al Retrospectively reviewed records of 4018 patients who received doxorubicin Definition of doxorubicin-induced CHF: Clinical signs/symptoms of CHF believed to be secondary to doxorubicin by the clinician Findings: Overall incidence: 2.2% (n=88). Inflection point at 550 mg/m 2 (7%) Adapted from Von Hoff et al. Ann Int Med. 1979;91:710-7.
6 Doxorubicin: Dose-Relationships 1979: Report by Von Hoff et al Retrospectively reviewed records of 4018 patients who received doxorubicin Definition of doxorubicin-induced CHF: Clinical signs/symptoms of CHF believed to be secondary to doxorubicin by the clinician Findings: Overall incidence: 2.2% (n=88). Inflection point at 550 mg/m 2 (7%) Adapted from Von Hoff et al. Ann Int Med. 1979;91:710-7.
7 A More Recent Look at the Data Analysis of the placebo-arms of three dexrazoxane trials In all trials: Normal LVEF at start MUGA performed at baseline & after every 50 mg/m 2 of doxorubicin Examined rate of significant EF drop or symptomatic HF Supported by recent trials (e.g. B-31 & N-9831) Adapted from Swain et al. Cancer. 2003;97:
8 Why Isn t This Curve Reproduced? x x x x x x x x x x x x x x Adapted from Von Hoff et al. Ann Int Med. 1979;91:710-7 and Swain et al. Cancer. 2003;97:
9 Sutent Label Do You Know What This Means? Sutent Prescribing Information (Pfizer), May 2011 Sutent Prescribing Information.
10 Hypothesis 2: Cardiotoxicity Definitions in CTCAE 4.0 Are in Desperate Need of Reform
11 Deserves praise far ahead of what we have in Cardiology CTCAE CTCAE : Major changes in definitions of cardiac toxicity Goal to improve cardiac monitoring Was the goal realized?
13 All located here
19 Problems With CTCAE 3.0 Troponin inconsistencies Diastolic dysfunction = Muddy water Defines EF 50-59% as Grade 1 LV systolic dysfunction, even though EF above 55% is generally considered normal Picking nits?
20 Good Things About CTCAE 3.0 All cardiac toxicities were located in one section If LVEF dropped, it was clear what it should be called (LV systolic dysfunction) & with clear description of grading Other than Grade 1 definition going to up to 59%, the grades of toxicity were fairly reasonable
21 CTCAE 4.0: A Step Backwards Increased number of cardiac toxicity terms from 15 to 36 (!) Created three different ways of grading the same event Misdefined left ventricular systolic dysfunction as A disorder characterized by failure of the left ventricle to produce adequate output despite an increase in distending pressure and in end-diastolic volume.
22 The World of CTCAE 4.0 Consider the case of a patient with an asymptomatic LVEF drop from 60% to 35% How should the Oncologist grade this according to CTCAE 4.0?
23 Turns to CTCAE 4.0 Table of Contents
24 Grade 0 or Grade 1?
25 But Wait
26 Maybe It s Grade 3?
27 One More Caveat: When Does an Event Count? Answer: When it is reported by the site investigator When might that make sense? Symptom or exam finding in which the subtlety of being the physician taking the history or performing the exam matters When might that not make sense? Objective laboratory or imaging finding Examples: Neutropenia, Drop in LVEF One more caveat: How likely is the event considered to be related to the intervention being studied? (TRAE) Large can of worms if dealing with unexpected side-effect
28 Hypothesis 3: Those Who Don t Learn From History Are Doomed to Repeat It
29 Sunitinib FDA approved in 2007 based on two Phase III clinical trials Currently under investigation for >30 tumor types in over 300 clinical trials! We can learn a lot from this story
30 Sunitinib: The Story Begins Phase 1 data/cardiotoxicity 15 patients with refractory/resistant AML treated with sunitinib Heart failure: 2/15 (without prospective imaging) One heart-failure mediated death, possibly related to the drug Data adapted from Fiedler et al. Blood. 2005;105:
31 Phase II Study More Worries 63 patients with metastatic renal cell CA All patients: Normal LVEF at start Cardiac monitoring: Echo or MUGA at the end of each cycle Ejection fraction decline to below normal (on 2 or more assessments): 11% of patients 6% removed from protocol for decline in EF Data adapted from Motzer et al. J Clin Onc. 2006;24:16-24.
32 Sunitinib First Phase III Trial Phase III study for GIST, Lancet patients given sunitinib or placebo Cardiac monitoring with MUGA performed at screening & the end of each cycle MUGA data not provided in article Time to Tumor Progression Overall Survival
33 Table of Adverse Events Adapted from Demetri et al. Lancet. 2006;368:
34 Sunitinib (Sutent): Data vs. Label Lancet GIST Study A, October 2006 Sutent Prescribing Information, February 2007 Sutent Prescribing Information. & Demetri et al. Lancet. 2006;
35 Sunitinib (Sutent): Data vs. Label Lancet GIST Study A, October 2006 Sutent Prescribing Information, February 2007 Sutent Prescribing Information. & Demetri et al. Lancet. 2006;
36 Sunitinib (Sutent): Data vs. Label Lancet GIST Study A, October 2006 Sutent Prescribing Information, February 2007 Sutent Prescribing Information. & Demetri et al. Lancet. 2006;
37 Sunitinib (Sutent): Data vs. Label Lancet GIST Study A, October 2006 Sutent Prescribing Information, February 2007 Sutent Prescribing Information. & Demetri et al. Lancet. 2006;
38 Sunitinib Second Phase III Study 750 patients with untreated metastatic renal-cell CA randomized to receive: Sunitinib Interferon alfa Normal LVEF at baseline Data adapted from Motzer et al. NEJM. 2007;356:
39 Heart Failure: Phase III Study Data adapted from Motzer et al. NEJM. 2007;356:
40 Study 2: More Confusion NEJM metastatic renal cell CA (MRCC) Study, January, 2007 Sutent Prescribing Information (Pfizer), February 2007 Sutent Prescribing Information. & Motzer et al. NEJM. 2007;356:
41 Study 2: More Confusion NEJM metastatic renal cell CA (MRCC) Study, January, 2007 Sutent Prescribing Information (Pfizer), February 2007 Sutent Prescribing Information. & Motzer et al. NEJM. 2007;356:
42 Study 2: More Confusion NEJM metastatic renal cell CA (MRCC) Study, January, 2007 Sutent Prescribing Information (Pfizer), February 2007 Sutent Prescribing Information. & Motzer et al. NEJM. 2007;356:
43 Study 2: More Confusion NEJM metastatic renal cell CA (MRCC) Study, January, 2007 Sutent Prescribing Information (Pfizer), February 2007 Sutent Prescribing Information. & Motzer et al. NEJM. 2007;356:
44 Which of These is Accurate? NEJM Treatment-Naïve MRCC Study, January 11, 2007 Sutent Prescribing Information (Pfizer), February 2007 Sutent Prescribing Information (Pfizer), May 2011 Sutent Prescribing Information. & Motzer et al. NEJM. 2007;356:
45 2011: Another Trial, Still Confusion 171 patients with PNET randomized to receive: Sunitinib Placebo Normal baseline EF No cardiac imaging built in! Note: First patient randomized in June 2007 Highlights how to this day this is thought to be a non-issue or trivial issue based on original Phase III publications Treatment-related heart failure deaths 2 out of 83 patients! Adapted from Raymond et al, NEJM. 2011;364:
46 Continued Inconsistencies: 2011 NEJM Phase III PNET Trial, Published February 10, 2011 Sutent Prescribing Information (Pfizer), May 2011 Sutent Prescribing Information. & Raymond et al, NEJM. 2011;364:
47 Continued Inconsistencies: 2011 NEJM Phase III PNET Trial, Published February 10, 2011 Sutent Prescribing Information (Pfizer), May 2011 Sutent Prescribing Information. & Raymond et al, NEJM. 2011;364:
48 Continued Inconsistencies: 2011 NEJM Phase III PNET Trial, Published February 10, 2011 Sutent Prescribing Information (Pfizer), May 2011 Sutent Prescribing Information. & Raymond et al, NEJM. 2011;364:
49 How Could This Happen? Adapted from Demetri et al. Lancet. 2006;368:
50 Misleading Reporting Authors explanation for lack of inclusion in table of adverse events in Lancet: The table summarized the TRAEs that occurred with a frequency of >5% on sunitinib compared with placebo. LVEF declines were not reported in this table since the frequency did not meet the criteria (6.4% vs. 2.0%). The product label, on the other hand, reports the frequency (11% for sunitinib versus 3% for placebo) of LVEF declines to below LLN as measured by MUGA scan. Quoted from response to letter to Lancet by Dr. Demetri, Dr. Motzer, and Dr. Baum (Pfizer).
51 How Could This Happen? NEJM Treatment-Naïve MRCC Study, January 11, 2007 Sutent Prescribing Information (Pfizer), February 2007 Sutent Prescribing Information. & Motzer et al. NEJM. 2007;356:
52 Misleading Reporting Authors explanation for difference in data from article vs. label in NEJM publication: In our assessment, TRAEs as reported by the investigators were clinically more informative and relevant for the purpose of journal publication than MUGA data. Quoted from response to letter to Lancet by Dr. Demetri, Dr. Motzer, and Dr. Baum (Pfizer).
53 TRAEs Lancet GIST study, October, 2007 NEJM Renal Cell CA study, January, 2007 Adapted from Motzer et al. NEJM. 2007;356: and Demetri et al. Lancet. 2006;
54 Let s Be Clear About What Is Being Put Forward The argument is not that the MUGA data was incorrect Rather, the argument is that if a site investigator doesn t report an EF drop as an AE (or considers it not to be treatment related ), there is no responsibility of the investigator to report it in the publication even with a clear signal. Note: The investigators had access to all of this data. In fact, this was the data the FDA insisted on Note 2: A statement like no systemic mean decrease in ejection fraction in the publication in hindsight appears clearly intended to mislead.
55 Hypothesis 4: This Matters
56 It Matters When This is Used to Guide Treatment Decisions in 2011 Adapted from Von Hoff et al. Ann Int Med. 1979;91:710-7.
57 It Matters: Subsequent Sunitinib Data Adapted from Chu et al. Lancet. 2007;370:
58 It Matters: Subsequent Stanford Data Reviewed all patients receiving sunitinib at Stanford from 7/04-7/07 1/3 in clinical trials, 2/3 off of clinical trials Asymptomatic EF monitoring not routinely performed for most patients Findings: 48 patients in cohort 7/48 (15%) developed Grades 3-5 heart failure Dramatic LVEF drops in all 7 cases Follow-up: 2 patients died from heart failure Adapted from Telli et al. Ann Oncol. 2008;19:
59 Relative Risk It Matters: RR of HF with Sunitinib (P<0.001) Adapted from Richards et al. J Clin Oncol. 2011;29:
60 Relative Risk of HF in Sunitinib Arm Screening Matters for Asymptomatic and Symptomatic Detection Adapted from Richards et al. J Clin Oncol. 2011;29: Note: Should not have theoretically needed screening
61 Conclusions What is needed: Get labeling up to date Reform of CTCAE Now! Don t rely on site investigators for reporting objective measures Consider all adverse events no hiding behind whether they re called treatment related Routine cardiac imaging built into more trials Honest trial reporting 5.0 We should not stand for reporting as has happened with sunitinib. Not trying to bring down development of cancer therapeutics Trying to make their use safer
62 One Final Thought People can forsee the future only when it coincides with their own wishes, and the most grossly obvious facts can be ignored when they are unwelcome. -George Orwell, 1945
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
DDD is Superior to VVI? Jeong-Gwan Cho, MD, FACC Division of Cardiology Chonnam University Hospital What is your answer? My answer is no, based on the several randomized clinical trials. The era of evidence-based
The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma Robert A. Figlin MD., FACP Acting Director City of Hope Comprehensive Cancer Center Cytoreductive Surgery
NIH/NCI Funding Opportunities for Cardio-Oncology Clinical Trials and Research Projects Lori Minasian, M.D., FACP Deputy Director NCI Division of Cancer Prevention September 30, 2016 Outline Perspective
Timing of TKI s pre- or post-nephrectomy Dr Simon Crabb Senior Lecturer and Honorary Consultant in Medical Oncology Cancer Sciences Unit, University of Southampton Faculty of Medicine Initial nephrectomy
Role and Potential of Surrogate Outcomes David L. DeMets, PhD University of Wisconsin Madison 1 Surrogate Response Variables Laboratory measurement used as alternative or substitute for desired or ideal
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
2013; 16 (2) Original article Poudel C M 1 Correspondence to : 1 Abstract Background: diagnosis, in the outcome of heart failure in the form of in hospital mortality is studied. Methods: Results: mortality.
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
Patient Reported Outcomes in Ovarian Cancer Clinical Trials - Missed Opportunities and Lessons Learned Michael Friedlander 1, Rebecca Mercieca-Bebber 2,3 and Madeleine King 2,3 1.Director of Research ANZGOG
General Considerations for Clinical Trial Design Steve Winitsky, M.D. Division of Clinical Evaluation and Pharmacology/Toxicology Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
Heart failure randomized clinical trials: how we changed standard of care. Karl Swedberg Senior professor of Medicine University of Gothenburg Professor of Cardiology Imperial College, London Disclosures:
Modified Early Warning Score (MEWS) Ruchika D. Husa, MD, MS Assistant t Professor of Medicine i in the Division of Cardiology The Ohio State University Wexner Medical Center MEWS Simple physiological scoring
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
Optimizing Timing of ICD Implant Post MI Cynthia M. Tracy, MD George Washington University Washington, DC No COI to declare % reduction Reduction in Total Mortality: ICD vs Control P=0.081 Boriani et al.
Hepatocellular Carcinoma: An Oncologist s Perspective March 6, 2015 Bruce Lin, M.D. Learning Objectives Treatment for advanced HCC Limitation of traditional chemotherapy in HCC Signaling pathways of hepatocarcinogenesis
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Research Study Protocol Template (For clinical trials) Instructions This protocol template is a tool to facilitate the development of a research study protocol specifically designed for the investigator
NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
Preview: Post-class quiz 5 - Clinical Trials Question 1 What is meant by "randomization"? (Select the one best answer.) Question 2 A. Selection of subjects at random. B. Randomization is a method of allocating
Cardiac Sarcoidosis N A B E E L H A M Z E H, M D N A T I O N A L J E W I S H H E A L T H D E N V E R, C O Disclosures PI: Celgene Cellular Therapeutics: Phase 1B, Multi-center, Open-label, Dose Escalation
NUCLEAR CARDIOLOGY AND CARDIO SPECT SestaMIBI SPECT Study can measure Perfusion and function of the left ventricle Pulmonary Uptake of the Radiotracer Ischemic Dilation of the left ventricle Each of these
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
PO: Pathologic Complete esponse Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, MD, MSc Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
BASIC STATISTICAL THEORY / 3 CHAPTER ONE BASIC STATISTICAL THEORY "Statistical methods are objective methods by which group trends are abstracted from observations on many separate individuals." 1 Medicine
Updates in Breast Cancer: Radiation Shirnett Matthews, MD Radiation Oncology Cancer Centers of the Carolinas Hughes et al. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 years of Age
Imaging of Muscular Dystrophy Cardiomyopathy Sadaf Bhutta Seattle Children s Hospital University of Washington NASCI 2015 San Diego, CA Financial: None Disclosures Off label use of Gadolinium in CMR Muscular
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill firstname.lastname@example.org Primary endpoints in Phase II trials Recently looked at journal articles
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
COST EFFECTIVENESS OF VS IN NEWLY DIAGNOSED MULTIPLE MYELOMA Mohamad A. Hussein, MD, 1 Mark Wildgust, PhD, 2 John Fastenau, MPH, RPh, 3 Catherine Tak Piech, MBA, 3 and the C2000-003 Study Group 1 The Cleveland
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
Breast cancer screening and prevention: Update from the USPSTF Mark H. Ebell MD, MS Member, USPSTF College of Public Health The University of Georgia What we re going to do today Overview of the USPSTF
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC email@example.com Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article  December 01, 2003 By George W. Sledge, Jr, MD  Gemcitabine (Gemzar) and paclitaxel show good activity as single
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone
TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER TAXOTERE -based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer Bridgewater,
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study
How to Use the Research Design Algorithm Below is a diamond by diamond guide for using the Research Design Algorithm developed by the Academy of Nutrition and Dietetics, 2010. Included are Tips on what
Sudden Cardiac Death in Heart Failure Dr David Sim Associate Consultant Heart Failure/Transplant National Heart Centre Singapore Introduction Ventricular arrhythmias common in HF Malignant or potentially
Goals of This Course Be able to understand a study design (very basic concept) Be able to understand statistical concepts in a medical paper Be able to perform a data analysis Understanding: PECO study
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
Evidence Based-Medicine: A Case Study of Vaccines and Autism Leah Liu Johnny Kung Alison Taylor Overview of Today s Lecture Leah: Introduction to Evidence-based medicine Johnny: Vaccines and Public Health
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
Telemedicine in the Prevention and Monitoring of Heart Disease Prof. Dr. med. Friedrich Köhler 26. April 2012 Charité-Universitätsmedizin Berlin Facts Founded in 1710 11 Nobel laureates 12.922 employees
Advance Care Planning with Heart Failure: Results of a Primary Care Practitioners Needs Survey 5 th Annual Nursing Research and Evidence Based Practice Symposium November 15, 2013 Ann Laramee MS ANP-BC
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
Current Challenges in Management of Aortic Stenosis? Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital No Relationships
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
Secondary Uses of Data for Comparative Effectiveness Research Paul Wallace MD Director, Center for Comparative Effectiveness Research The Lewin Group Paul.Wallace@lewin.com Disclosure/Perspectives Training:
Practice Guideline: Systemic Therapy Summary Primary Curative Therapy for Head and Neck Squamous Cell Carcinoma with Cetuximab in Combination with Radiation (Head & Neck Cetuximab with Radiation) Effective:
Cancer Treatment and the Heart Cardio-Oncology September 12, 2014 Randolph P. Martin, MD, FACC, FASE, FESC Chief Structural and Valvular Heart Disese Center of Excellence Principal Advisor Marcus Heart
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
Cholesterol Treatment Trialists (CTT) Collaboration Slide deck CTT Collaboration: Background* History: Founded in 1993 (prior to publication of 4S trial in 1994) Original protocol published in 1995 Trial
AKB-6548 clinical development overview early clinical studies (CI-0001 to CI- 0004, and CI-0006) To date, AKB-6548 has been studied in 8 clinical trials across 4 separate patient populations: healthy volunteers
January 2012 Purpose of the Project The human and financial costs of cardiovascular disease are enormous. Heart disease is the leading cause of death for men and women in the United States and was estimated
National Cancer Institute Division of Cancer Prevention Serious Adverse Event Form Instructions for Completion Version 1.2 SAE Report Form: Instructions for Completion Version 1.2 DOCUMENT CHANGE RECORD
Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
IT S TIME FOR A SERIOUS DISCUSSION WITH YOUR ONCOLOGIST ABOUT THEIR CHEMOTHERAPY DOSING PLAN FOR YOU. Since you ve found your way to this doctor discussion guide, you already know a lot. You know there